Medical indications and considerations for future clinical decision making

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Thrombosis Research

Background:

• Current antithrombotic agents (warfarin, heparin, LMWHs) have significant limitations including parenteral administration and the need for regular monitoring.
• Oral administration and predictable pharmacokinetics are desirable for antithrombotic therapy.

Purpose of the Study:

• To evaluate the efficacy and tolerability of ximelagatran, an oral direct thrombin inhibitor.
• To compare ximelagatran with standard antithrombotic therapies across various clinical indications.

Main Methods:

• Clinical trials evaluating ximelagatran for prophylaxis and treatment of venous thromboembolism (VTE).
• Studies assessing stroke prevention in atrial fibrillation (AF) and cardiovascular event prevention in acute coronary syndromes.
• Investigation of ximelagatran in combination with aspirin for acute coronary artery disease management.

Main Results:

• Ximelagatran is well tolerated at doses up to 60 mg twice daily.
• Oral ximelagatran demonstrated efficacy comparable to standard therapy in preventing thromboembolic events post-hip/knee surgery and treating deep vein thrombosis (DVT).
• Effective in stroke prevention for nonvalvular AF patients and in managing acute coronary syndromes.

Conclusions:

• Ximelagatran offers a favorable profile as an oral antithrombotic agent.
• Fixed-dose, twice-daily oral administration of ximelagatran eliminates the need for routine coagulation monitoring.
• Ximelagatran presents a viable and effective alternative to existing antithrombotic treatments.